Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Musculoskeletal  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Multiple Myeloma Clinical Trials

A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (61) clinical trials

This study will be conducted in 2 parts. The phase 1b part will be an international, phase 1b, open-label, dose-escalation assessment of radium-223 dichloride administered with bortezomib and dexamethasone in subjects with relapsed multiple myeloma. The primary endpoint is to determine the optimal dose of radium-223 dichloride in combination with ...

Phase

Ixazomib ONC201 and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Phase I Study Design Phase I will follow a 3+3 dose escalation design to determine the RPTD of ixazomib in combination with ONC201 and Dexamethasone. The dose escalation rules for the phase I portion of the study are as follows, escalating in cohorts of 3 patients per dose level including ...

Phase

Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma

In the currently proposed phase I/II study, the investigators aim to treat patients with relapsed and/or relapsed refractory multiple myeloma (MM) who have progressed on carfilzomib-based therapy with an FDA approved c-MET inhibitor, cabozantinib. Our hypothesis is that the additional rescue blockade with cabozantinib added to the carfilzomib will (1) ...

Phase

SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

A Phase 1/2, Open Label Study of SL-401 in Combination with Pomalidomide and Dexamethasone In Relapsed and Refractory Multiple Myeloma. This study is a Phase 1/2 multi center, open label study of SL-401 in combination with standard doses of Pomalidomide and Dexamethasone. The study will be conducted in 2 Phases: ...

Phase

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

This Phase I/IIA, open label, multicenter, dose escalation study of CB-103 in patients with Advanced or Metastatic Solid Tumours and Haematological Malignancies. After providing signed informed consent, patients will be screened for entry into the study. The study will be conducted in 2 stages. In a dose escalation stage, approximately ...

Phase

ABC294640 in Refractory / Relapsed Multiple Myeloma

Objectives for Phase 1b: Primary Objectives To assess safety and determine the maximum tolerated dose (MTD) of single agent ABC294640 in patients with refractory or relapsed multiple myeloma (MM) who have been previously treated with proteasome inhibitors and immunomodulatory agents. Secondary Objectives To assess the antitumor activity of single agent ...

Phase

ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma

This is a single institution, prospective, phase I/II open-label study in a maximum of 20 patients evaluating a novel treatment strategy in NDMM patients with high-risk disease who do not have a 6/6 compatible sibling donor. Participating patients will be from Hpital Maisonneuve-Rosemont (HMR) or referred to HMR for this ...

Phase

Ixazomib With Pomalidomide Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma

PRIMARY OBJECTIVES: I. To establish the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) for PiC-D therapy (pomalidomide, ixazomib [ixazomib citrate], clarithromycin, and dexamethasone) in patients with multiple myeloma who are bortezomib and lenalidomide refractory. (Phase I) II. To determine the complete response (CR) and stringent CR ...

Phase

Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma

Multiple myeloma (MM) is a malignancy of plasma cells, which remains a clinical challenge despite advanced therapeutic interventions including novel molecular therapies and stem cell transplantation (SCT). This trial is to test the safety and efficacy of T cells genetically modified to specifically target several MM surface antigens, including BCMA, ...

Phase

A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies

B-cell maturation antigen(BCMA) is preferentially expressed in mature B lymphocytes as well as in B-cell derived leukemia, lymphomas, and multiple myeloma. Despite of the fact that CD19-targeted CAR-T can re-induce remissions for many patients with relapsed and refractory B cell malignancies, a part of those patients will relapse with CD19-negative ...

Phase